Sunitinib
- TRADE NAME: Sutent (Pfizer)
- INDICATIONS: Gastrointestinal stromal tumor, advanced renal cell carcinoma, advanced pancreatic neuroendocrine tumor
- CLASS: Antineoplastic / anticancer agent, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 40–60 hours
Atazanavir, Bevacizumab, Carbamazepine, Clarithromycin, Clozapine, Dexamethasone, Digoxin, Efavirenz, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Temsirolimus, Voriconazole
PREGNANCY CATEGORY: D
[G] = treated for gastrointestinal tumor; [R] = treated for renal cell carcinoma; [P] treated for pancreatic neuroendocrine tumor
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sunitinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/02/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
